The long road to immunotherapy for childhood rhabdomyosarcoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

1. Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma.Cancer immunology, immunotherapy : CII · 2016
   Article
2. Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.Oncogene · 2014
   Review

Corrections and comments

• Comment on
  Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.2011

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as